Ozempic maker to testify before Senate committee on weight loss drug prices
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on Tuesday.
The five pillars of cancer care currently comprise surgery, radiotherapy, traditional chemotherapy, precision therapy, and immunotherapy. Each of these treatments addresses cancer in different ways, targeting the malignancy itself. However, the link between obesity and cancer has been well established, and obesity has been recognized as a risk factor for certain types of cancer. Given the strong correlation between obesity and cancer risk, including potential molecular mechanisms that may foster cancer growth, an emphasis on weight management could represent a profound shift in cancer prevention and treatment.
The integration of obesity management into the treatment paradigm could involve a multidisciplinary approach, incorporating dietary interventions, physical activity, behavioral changes, and potentially even novel pharmacological agents aimed at curbing weight gain. By addressing obesity as a modifiable risk factor, healthcare professionals may be able to not only treat cancer more effectively but also prevent it in certain instances. The introduction of weight management as another pillar in cancer care would require rigorous scientific research and clinical trials. However, if successfully implemented, it could revolutionize the way we approach cancer treatment and prevention, placing a strong emphasis on the patient’s overall well-being and lifestyle choices, and ushering in a new era of holistic cancer care.
It is the purpose of this website to draw attention to this unmet need in medicine and to address some of the questions that surround this new medical field.
Obesity is a major health concern that is not only associated with chronic diseases like cardiovascular disease, but it is also linked with an increased risk of cancer. According to the National Institutes of Health (NIH), 4-8% of all cancers can be attributed to obesity. The underlying mechanism of obesity causing cancer is complex, and researchers are still trying to gain a better understanding of it. However, researchers know that certain lifestyle changes can help reduce the risk of developing cancer due to obesity. In particular, diet, exercise, and behavior therapy are the mainstay of intervention to fight against obesity and, thereby, lower the risk of cancer. For more information, please click on the link to the research paper cited and also check out the NIH’s National Cancer Institute infographic on the cancers associated with overweight and obesity.
This webpage from the Centers for Disease Control and Prevention (CDC) explores the strong link between obesity and cancer risk. It outlines how being overweight or obese increases the likelihood of developing 13 specific types of cancer, which account for 40% of all cancer diagnoses in the United States. The article also discusses how excess weight can lead to bodily changes, such as inflammation and hormone imbalances, which contribute to cancer development. Finally, the CDC provides practical steps for individuals and healthcare providers to reduce the risk of obesity-related cancers, emphasizing the importance of healthy lifestyle choices and preventative measures.
The Link Between Obesity and Cancer provides a comprehensive and up-to-date review of the relationship between obesity and cancer. It opens with a global perspective on obesity and cancer incidence, followed by in-depth discussions on cancers for which we have sufficient and new evidence of a causal relationship with obesity. Readers will gain fundamental knowledge about which different cancer types are related to obesity and why. The book provides a significant knowledge base for clinicians to know when to act, along with specific management guidelines for patients with obesity as well as how to understand the potential risk factors and how to directly or indirectly minimize these risks. The book also provides scientific data for any researcher in the field, identifying the molecular mechanisms and links behind the development of malignancy and promoting research on new affective target pathways m developing therapeutic strategies.
Key Features
• Provides essential knowledge on how to understand the link between obesity and cancer and why and how this occurs; enables readers to gain fundamental knowledge on which cancer types are related to obesity and why
• Provides a significent knowledge base for clinicians on when to act, along with patient management guidelines for patients with obesity as well as how to understand potential risk factors and how to minimize them
• Contains new scientific data and findings for researchers, which identify the molecular mechanisms and links behind the development of malignancy
The book, The Link Between Obesity and Cancer on sale at Amazon or at ScienceDirect®.
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on Tuesday.
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy. Here’s what to expect.
In a new push to make popular weight loss drugs more affordable, the CEO of Novo Nordisk is set to face a grilling on Capitol Hill over the high cost of Ozempic, used to treat
Recent research easing suicidality concerns about GLP-1s and suggesting potential psychiatric benefit has led to a call for further study of these drugs for mental illness. Medscape Medical News
Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify on Capitol Hill Tuesday.
Physicians fear use of weight loss drugs in teens will increase or exacerbate eating disorder cases, adding complexity to treatment. Medscape Medical News
This JAMA Data Brief discusses new data from the Medical Expenditure Panel Survey, or MEPS, Household Component, a household survey sponsored by the Agency for Healthcare Research and Quality.
Novo Nordisk’s blockbuster diabetes drug Ozempic will be eligible for U.S. government’s price negotiations in less than a year based on current criteria, the Danish… Reuters Health Information
Please subscribe to our weekly newsletter. We cover the news about obesity and cancer and about the new drugs that are coming onto the market. We do not sell or give away your name or email addresses.